TY - JOUR
T1 - Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study
AU - Hanly, John G.
AU - Urowitz, Murray B.
AU - Su, Li
AU - Gordon, Caroline
AU - Bae, Sang Cheol
AU - Sanchez-Guerrero, Jorge
AU - Romero-Diaz, Juanita
AU - Wallace, Daniel J.
AU - Clarke, Ann E.
AU - Ginzler, E. M.
AU - Merrill, Joan T.
AU - Isenberg, David A.
AU - Rahman, Anisur
AU - Petri, M.
AU - Fortin, Paul R.
AU - Gladman, D. D.
AU - Bruce, Ian N.
AU - Steinsson, Kristjan
AU - Dooley, M. A.
AU - Khamashta, Munther A.
AU - Alarcón, Graciela S.
AU - Fessler, Barri J.
AU - Ramsey-Goldman, Rosalind
AU - Manzi, Susan
AU - Zoma, Asad A.
AU - Sturfelt, Gunnar K.
AU - Nived, Ola
AU - Aranow, Cynthia
AU - Mackay, Meggan
AU - Ramos-Casals, Manuel
AU - Van Vollenhoven, R. F.
AU - Kalunian, Kenneth C.
AU - Ruiz-Irastorza, Guillermo
AU - Lim, Sam
AU - Kamen, Diane L.
AU - Peschken, Christine A.
AU - Inanc, Murat
AU - Theriault, Chris
AU - Thompson, Kara
AU - Farewell, Vernon
PY - 2012/9
Y1 - 2012/9
N2 - Objective: The aim of this study was to describe the frequency, attribution, outcome and predictors of seizures in systemic lupus erythematosus (SLE). Methods: The Systemic Lupus International Collaborating Clinics, or SLICC, performed a prospective inception cohort study. Demographic variables, global SLE disease activity (SLE Disease Activity Index 2000), cumulative organ damage (SLICC/American College of Rheumatology Damage Index (SDI)) and neuropsychiatric events were recorded at enrolment and annually. Lupus anticoagulant, anticardiolipin, anti-β 2glycoprotein-I, antiribosomal P and anti-NR2 glutamate receptor antibodies were measured at enrolment. Physician outcomes of seizures were recorded. Patient outcomes were derived from the SF-36 (36-Item Short Form Health Survey) mental component summary and physical component summary scores. Statistical analyses included Cox and linear regressions. Results: The cohort was 89.4% female with a mean follow-up of 3.5±2.9 years. Of 1631 patients, 75 (4.6%) had ≥1 seizure, the majority around the time of SLE diagnosis. Multivariate analysis indicated a higher risk of seizures with African race/ethnicity (HR (CI): 1.97 (1.07 to 3.63); p=0.03) and lower education status (1.97 (1.21 to 3.19); p
AB - Objective: The aim of this study was to describe the frequency, attribution, outcome and predictors of seizures in systemic lupus erythematosus (SLE). Methods: The Systemic Lupus International Collaborating Clinics, or SLICC, performed a prospective inception cohort study. Demographic variables, global SLE disease activity (SLE Disease Activity Index 2000), cumulative organ damage (SLICC/American College of Rheumatology Damage Index (SDI)) and neuropsychiatric events were recorded at enrolment and annually. Lupus anticoagulant, anticardiolipin, anti-β 2glycoprotein-I, antiribosomal P and anti-NR2 glutamate receptor antibodies were measured at enrolment. Physician outcomes of seizures were recorded. Patient outcomes were derived from the SF-36 (36-Item Short Form Health Survey) mental component summary and physical component summary scores. Statistical analyses included Cox and linear regressions. Results: The cohort was 89.4% female with a mean follow-up of 3.5±2.9 years. Of 1631 patients, 75 (4.6%) had ≥1 seizure, the majority around the time of SLE diagnosis. Multivariate analysis indicated a higher risk of seizures with African race/ethnicity (HR (CI): 1.97 (1.07 to 3.63); p=0.03) and lower education status (1.97 (1.21 to 3.19); p
U2 - 10.1136/annrheumdis-2011-201089
DO - 10.1136/annrheumdis-2011-201089
M3 - Article
C2 - 22492779
SN - 0003-4967
VL - 71
SP - 1502
EP - 1509
JO - Annals of the rheumatic diseases
JF - Annals of the rheumatic diseases
IS - 9
ER -
